Pharmacokinetics of YK754, a novel If channel inhibitor in rats, dogs and humans

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 33, Issue 2, 2008, Pages 117-127

  Umehara, K I ^a   Nakamata, T ^b   Suzuki, K ^a   Noguchi, K ^a   Usui, T ^a   Kamimura, H ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

Blood cell transfer; First pass effect; If channel inhibitor; Pharmacokinetics; Plasma protein binding

Indexed keywords

CARDIOVASCULAR AGENT; N [2 [3 (6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLINE 2 CARBONYL)PIPERIDINO]ETHYL] 4 FLUOROBENZAMIDE MONOPHOSPHATE; OROSOMUCOID; YM 758;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; FIRST PASS EFFECT; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; LIVER; LIVER BLOOD FLOW; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NONLINEAR SYSTEM; PARTITION COEFFICIENT; PLASMA PROTEIN BINDING; RAT; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 51049101311     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191028     Document Type: Article

References (10)

1. Bucchi A., Barbuti A., Baruscotti M., DiFrancesco D. (2007): Heart rate reduction via selective 'funny' channel blockers. Curr. Opin. Pharmacol., 7, 208-213.
2. Indolfi C., Guth B.D., Miura T., Miyazaki S., Schulz R., Ross J Jr. (1989): Mechanisms of improved ischemic regional dysfunction by bradycardia. Studies on UL-FS 49 in swine. Circulation, 80, 983-993.
3. Roth W., Bauer E., Heinzel G., Cornelissen P.J., van Tol R.G., Jonkman J.H., Zuiderwijk P.B. (1993): Zatebradine: pharmacokinetics of a novel heart-rate-lowering agent after i.v. infusion and oral administration to healthy subjects. J. Pharma. Sci., 82, 99-106.
4. Umehara K.I., Seya K., Sonoda T., Nakamura E., Noguchi K., Usui T., Kamimura H. (2008): Comparative evaluation of absorption, distribution, and excretion of YM758, a novel If channel inhibitor, between albino and non-albino rats. Xenobiotica, 38, 527-539.
5. Umehara K., Iwai M., Adachi Y., Usui T., Iwatsubo T., Kamimura H. (2008): Hepatic uptake and excretion of YM758, a novel If channel inhibitor, in rats and humans. Drug Metab. Pharmacokinet., 36, 1030-1038.
6. Leon S., Andrew Y. (1999): Applied Biopharmaceutics & Pharmacokinetics, 4th edn. CT, USA: Appleton & Lange.
7. Dedrick R.L., Zaharko D.S., Lutz R.J. (1973): Transport and binding of methotrexate in vivo. J. Pharm. Sci., 62, 882-890.
8. Wacher V.J., Silverman J.A., Zhang Y., Benet L.Z. (1998): Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci., 87, 1322-1330.
9. Greenway C.V., Stark R.D. (1971): Hepatic vascular bed. Physiol. Rev., 51, 23-65.
10. Iwatsubo T., Suzuki H., Sugiyama Y. (1997): Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. J. Pharmacol. Exp. Ther., 283, 462-469.